drugset
drugset / Trial / NCT04570267

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects

NCT04570267 ↗

Phase 1 Completed 32 enrolled CSL Behring
RandomizedSequentialTriple-blindTreatment

Summary

Study CSL324\_1003 is a single center, randomized, double-blind, placebo-controlled study designed to characterize and compare the PK properties and safety of a single subcutaneous dose of CSL324 in healthy Japanese and White subjects.

Timeline

Start
2020-10-08
Primary completion
2021-11-17
Completion
2021-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Anumigilimab Monoclonal antibody — Subcutaneous

Indications

No indication recorded.